Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer

British Journal of Cancer

Volumn 103, Issue 7, 2010, Pages 1048-1056

  Ihnen, M ^a   Wirtz, R M ^b   Kalogeras, K T ^c,d   Milde Langosch, K ^a   Schmidt, M ^e   Witzel, I ^a   Eleftheraki, A G ^d   Papadimitriou, C ^f   Janicke F ^a   Briassoulis, E ^g   Pectasides, D ^h   Rody, A ⁱ   Fountzilas, G ^c   Muller V ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Siemens Healthcare Diagnostic Products   (Germany)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d Hellenic Cooperative Oncology Group   (Greece)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f UNIVERSITY OF ATHENS   (Greece)

^g UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^h NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

ⁱ GOETHE UNIVERSITY   (Germany)

Author keywords

ALCAM; discriminative markers; HER2 and ER negative breast cancer; osteopontin

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; OSTEOPONTIN; EIF3A PROTEIN, HUMAN; ESTROGEN RECEPTOR; INITIATION FACTOR 3;

ADULT; AGED; ARTICLE; BREAST CANCER; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BREAST TUMOR; DECISION TREE; DNA MICROARRAY; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; RISK;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; ADULT; AGED; BREAST NEOPLASMS; CLUSTER ANALYSIS; DECISION TREES; DISEASE-FREE SURVIVAL; EUKARYOTIC INITIATION FACTOR-3; FEMALE; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RISK; RNA, MESSENGER;

EID: 77957237558     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605840     Document Type: Article

References (24)

1. Andersen H, Mahmood S, Tkach V, Cohn M, Kustikova O, Grigorian M, Berezin V, Bock E, Lukanidin E, Tulchinsky E (2002) The ability of Fos family members to produce phenotypic changes in epitheloid cells is not directly linked to their transactivation potentials. Oncogene 21: 4843-4848 (Pubitemid 34879460)
2. Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23: 2162-2171 (Pubitemid 46218708)
3. Burkhardt M, Mayordomo E, Winzer KJ, Fritzsche F, Gansukh T, Pahl S, Weichert W, Denkert C, Guski H, Dietel M, Kristiansen G (2006) Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol 59: 403-409
4. Chakraborty G, Jain S, Kundu GC (2008) Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 68: 152-161 (Pubitemid 351380116)
5. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF (2005) Osteopontin induces multiple changes in gene expression that reflect the six hallmarks of cancer in a model of breast cancer progression. Mol Carcinogenesis 43: 225-236 (Pubitemid 41134430)
6. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14: 5158-5165
7. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25: 3994-4008 (Pubitemid 43990755)
8. Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C, Bafaloukos D, Lambropoulos S, Papadopoulos S, Kourea H, Markopoulos C, Linardou H, Mavroudis D, Briasoulis E, Pavlidis N, Razis E, Kosmidis P, Gogas H (2005) Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat 92: 1-9 (Pubitemid 40875072)
9. Ihnen M, Müller V, Wirtz RM, Schröder C, Krenkel S, Witzel I, Lisboa B, Jänicke F, Milde-Langosch K (2008) Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) expression in breast cancer. Breast Cancer Res Treatm 112: 419-427
10. Kim C, Tang G, Baehner FL, Watson D, Costantino JP, Paik S, Shak S, Wolmark N (2006) A comparison of estrogen receptor (ER) measurement by three methods in node-negative, estrogen receptor (ER) positive breast cancer: ligand binding (LB), immunohistochemistry (IHC), and quantitative RT-PCR. Breast Cancer Res Treatm 100(Suppl 1): 3116
11. King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG (2004) Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 6: R478-R487
12. Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, Tanaka K, Rashid MM, Inobe M, Chambers AF, Uede T (2000) Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 77: 487-498 (Pubitemid 30230602)
13. Kristiansen G, Pilarsky C, Wissmann C, Stephan C, Weissbach L, Loy V, Loening S, Dietel M, Rosenthal A (2003) ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 54: 34-43 (Pubitemid 36043834)
14. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, Reinhardt F, Harris LN, Hylander BL, Repasky EA, Weinberg RA (2008) Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133: 994-1005 (Pubitemid 351787747)
15. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23: 9067-9072 (Pubitemid 46260161)
16. Milde-Langosch K, Janke S, Wagner I, Schröder C, Streichert T, Bamberger A-M, Jänicke F, Löning T (2008) Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility. Breast Cancer Res Treatm 107: 337-347 (Pubitemid 351172111)
17. Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H (2004) Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res 10: 6418-6431 (Pubitemid 39346536)
18. Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G (2009) Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat 116: 131-143
19. Rakha E, El-Sayed M, Green A, Lee A, Robertson J, Ellis I (2007) Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32 (Pubitemid 46120191)
20. Rudland PS, Platt-Higgins A, El-Tanani M, de Silva Rudland S, Barraclough R, Winstanley JHR, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62: 3417-3427 (Pubitemid 34651388)
21. Swart GWM, Lunter PC, van Kilsdonk JWJ, van Kempen LCLT (2005) Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Met Rev 24: 223-236
22. Verma A, Shukla NK, Deo SV, Gupta SD, Ralhan R (2005) MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology 68: 462-470 (Pubitemid 41160978)
23. Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G (2004) ALCAM/ CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 57: 1160-1164 (Pubitemid 39486521)
24. Zamagni C, Wirtz RM, De Iaco P, Rosati M, Veltrup E, Rosati F, Capizzi E, Cacciari N, Alboni C, Bernardi A, Massari F, Quercia S, DErrico Grigioni A, Dietel M, Sehouli J, Denkert C, Martoni AA (2009) Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neoadjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. Endocr Relat Cancer 16: 1241-1249